Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AN2 Therapeutics, Inc.ANTX · Entity 1085 | Chief Strategy Officer | January 05, 2026 | January 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AN2 Therapeutics, Inc.
Report date January 05, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,086 |
Last balance in matching sequence
After 2026-01-06 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-01-05 · Sale · Disposed 3,604 · Balance 61,944 F1: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026. F2: Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (b) a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024. On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026; and (c) 28,000 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. Row 2 · 2026-01-06 · Sale · Disposed 2,858 · Balance 59,086 F1: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026. F2: Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (b) a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024. On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026; and (c) 28,000 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026.
F2: Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (b) a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024. On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026; and (c) 28,000 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2026 Filed Jan 7, 2026 20:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 2,858 | $1.01 | $2,892.30 |
DisclosureSEC source: 0001193125-26-006770 · ownership.xml · nonDerivative · entry 2 Prior Stephen David · CIK 0002042268 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,086 F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026. F2 · balance_after: Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (b) a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024. On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026; and (c) 28,000 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 20:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 3,604 | $1.00 | $3,614.81 |
DisclosureSEC source: 0001193125-26-006770 · ownership.xml · nonDerivative · entry 1 Prior Stephen David · CIK 0002042268 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,944 F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026. F2 · balance_after: Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (b) a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024. On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026; and (c) 28,000 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 18:11 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 765 | $1.14 | $872.10 |
DisclosureSEC source: 0001193125-25-270252 · ownership.xml · nonDerivative · entry 1 Prior Stephen David · CIK 0002042268 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,548 F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on November 4, 2025. F2 · balance_after: Includes, in accordance with the original terms, (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 and (b) 12,031 RSUs which shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. F3 · balance_after: Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2025. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 16:19 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 56,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0000950170-25-030032 · ownership.xml · derivative · entry 2 Prior Stephen David · CIK 0002042268 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2035-02-25 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 16:19 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-030032 · ownership.xml · nonDerivative · entry 1 Prior Stephen David · CIK 0002042268 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,313 F1 · shares: Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date. F2 · balance_after: Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 and (b) 12,031 RSUs which shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 19:57 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 2,029 | $1.34 | $2,720.89 |
DisclosureSEC source: 0000950170-25-003153 · ownership.xml · nonDerivative · entry 1 Prior Stephen David · CIK 0002042268 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,313 F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2025. F2 · balance_after: Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 and (b) 12,031 RSUs which shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 16:57 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 20,250 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0000950170-24-121601 · ownership.xml · derivative · entry 2 Prior Stephen David · CIK 0002042268 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,250 Underlying: Common Stock · 20,250 shares Expires 2034-11-03 F3 · derivative.exercise_date: The shares subject to the option are exercisable and vest as follows: 1/48th of the shares vest and becomes exercisable monthly over four years from November 4, 2024 until fully vested and exercisable on November 4, 2028, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 16:57 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 10,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-121601 · ownership.xml · nonDerivative · entry 1 Prior Stephen David · CIK 0002042268 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,342 F1 · shares: Represents a grant of Restricted Stock Units ("RSUs"). RSUs vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, subject to the Reporting Person's continuous service as of such date. F2 · balance_after: Includes a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024. On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.